NYSE:JNJ
134.17
1.02
(0.77%)
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886.
More at Wikipedia
Analysis and Opinions about JNJ-N
Signal
Opinion
Expert
TOP PICK
TOP PICK
March 30, 2020
He would be a buyer here as it has dropped so much from the last time he recommended it. They announced they have something related to COVID-19 vaccination and can start human trials in late September. (Analysts’ price target is $157.85)
Show full opinionHide full opinion
He would be a buyer here as it has dropped so much from the last time he recommended it. They announced they have something related to COVID-19 vaccination and can start human trials in late September. (Analysts’ price target is $157.85)
TOP PICK
TOP PICK
March 12, 2020
Defensive. One of the largest healthcare companies in the world. Medical devices, pharma, personal care products. Great story. Consistent dividend grower. Talcum litigation issue has been dealt with. Very stable company. Yield is 3.03%. (Analysts’ price target is $159.84)
Show full opinionHide full opinionDefensive. One of the largest healthcare companies in the world. Medical devices, pharma, personal care products. Great story. Consistent dividend grower. Talcum litigation issue has been dealt with. Very stable company. Yield is 3.03%. (Analysts’ price target is $159.84)
TOP PICK
TOP PICK
February 28, 2020
It's been sideways for a couple years. This week, it shot down but he believes it will get back out to where it was before. It can definitely break out after recovery. They have more divisions than just pharma, like pet items. (Analysts’ price target is $160.28)
Show full opinionHide full opinionIt's been sideways for a couple years. This week, it shot down but he believes it will get back out to where it was before. It can definitely break out after recovery. They have more divisions than just pharma, like pet items. (Analysts’ price target is $160.28)
TOP PICK
TOP PICK
February 27, 2020
Model price is $182.97 or 28% upside. He likes the company and thinks it has good upside. (Analysts’ price target is $160.28)
Show full opinionHide full opinionModel price is $182.97 or 28% upside. He likes the company and thinks it has good upside. (Analysts’ price target is $160.28)
PAST TOP PICK
PAST TOP PICK
February 26, 2020
(A Top Pick Dec 16/19, Up 2%) A defensive name but durable. You're paid to wait. This applies to his other two past picks today, too.
Show full opinionHide full opinion(A Top Pick Dec 16/19, Up 2%) A defensive name but durable. You're paid to wait. This applies to his other two past picks today, too.
PAST TOP PICK
PAST TOP PICK
January 21, 2020
(A Top Pick Nov 19/19, Up 11%) The gains have surprised him. Good. If you're holding long-term, continue to hold. If you're trading this, you can do it now.
Show full opinionHide full opinion(A Top Pick Nov 19/19, Up 11%) The gains have surprised him. Good. If you're holding long-term, continue to hold. If you're trading this, you can do it now.
BUY
BUY
January 14, 2020
Has long owned this. It's attractively valued in this space. Likes their diversity--pharmaceutical (many new products), medical devices, and consumer products. Litigation overhang (talcum powder lawsuit) is an overhang. JNJ continues to raise their 3% dividend. Has a strong balance sheet. You can start buying it here if you are a long-term investor.
Show full opinionHide full opinionHas long owned this. It's attractively valued in this space. Likes their diversity--pharmaceutical (many new products), medical devices, and consumer products. Litigation overhang (talcum powder lawsuit) is an overhang. JNJ continues to raise their 3% dividend. Has a strong balance sheet. You can start buying it here if you are a long-term investor.
TOP PICK
TOP PICK
January 10, 2020
His model price is $190.40 -- over 30% upside, he believes. He does not expect the talc problem to an issue and creates a great opportunity to buy in. Yield 2.6% (Analysts’ price target is $156.06)
Show full opinionHide full opinionHis model price is $190.40 -- over 30% upside, he believes. He does not expect the talc problem to an issue and creates a great opportunity to buy in. Yield 2.6% (Analysts’ price target is $156.06)
TOP PICK
TOP PICK
January 8, 2020
In an election year, these kind of stocks get beaten, but JNJ is highly diversified in three divisions including personal products and are not merely into drugs which is a target of politicians in a US election year. JNJ has raised its dividend in each of the past 50 years. Trades at a decent 16x earnings. JNJ faces many lawsuits, but they staunchly defend themselves through appeals. (Analysts’ price target is $154.41)
Show full opinionHide full opinionIn an election year, these kind of stocks get beaten, but JNJ is highly diversified in three divisions including personal products and are not merely into drugs which is a target of politicians in a US election year. JNJ has raised its dividend in each of the past 50 years. Trades at a decent 16x earnings. JNJ faces many lawsuits, but they staunchly defend themselves through appeals. (Analysts’ price target is $154.41)
BUY
BUY
December 19, 2019
Given the opiate crisis They have three businesses-- so they're not volatile. Yes, they have issues with talcum, but have been winning those lawsuits. JNJ wasn't as big into opiates as other companies.
Show full opinionHide full opinionGiven the opiate crisis They have three businesses-- so they're not volatile. Yes, they have issues with talcum, but have been winning those lawsuits. JNJ wasn't as big into opiates as other companies.
BUY
BUY
December 18, 2019
SYK vs. JNJ SYK makes medical products while JNJ also produces that plus pharma and personal care products, but are fighting talcum powder lawsuits that will persist. Despite this, he much prefers JNJ due to better diversification and valuation. But wait for a better entry point.
TOP PICK
TOP PICK
December 16, 2019
Breaking news: found not guilty of misleading the public with its baby powder. A behemoth, well-diversified trading at an attractive 16x earnings and 5% free cash flow yield. A defensive name today. (Analysts’ price target is $150.28)
Show full opinionHide full opinionBreaking news: found not guilty of misleading the public with its baby powder. A behemoth, well-diversified trading at an attractive 16x earnings and 5% free cash flow yield. A defensive name today. (Analysts’ price target is $150.28)
TOP PICK
TOP PICK
December 11, 2019
If you look at the aggregate liabilities of the talcum powder legal issue, the market has over-estimated the impact on the company, he believes. The litigation could be on-going for years to come and the time value of money works in their favour. Yield 2.69% (Analysts’ price target is $150.28)
Show full opinionHide full opinionIf you look at the aggregate liabilities of the talcum powder legal issue, the market has over-estimated the impact on the company, he believes. The litigation could be on-going for years to come and the time value of money works in their favour. Yield 2.69% (Analysts’ price target is $150.28)
TOP PICK
TOP PICK
December 5, 2019
The drug space all have huge upsides. He has owned it for quite some time. Model rice is $185.42 which is a 33% upside. There is a lot of value here. (Analysts’ price target is $150.39)
Show full opinionHide full opinionThe drug space all have huge upsides. He has owned it for quite some time. Model rice is $185.42 which is a 33% upside. There is a lot of value here. (Analysts’ price target is $150.39)
DON'T BUY
DON'T BUY
November 21, 2019
JNJ vs PG He'd choose PG. JNJ has lawsuits still hanging around. Since mid-summer of 2018, JNJ has underperformed PG. Watch out for valuations. PG is trading at 24x, with a 7% growth rate. PG is the largest consumer name out there and will continue to grow.
Show full opinionHide full opinionJNJ vs PG He'd choose PG. JNJ has lawsuits still hanging around. Since mid-summer of 2018, JNJ has underperformed PG. Watch out for valuations. PG is trading at 24x, with a 7% growth rate. PG is the largest consumer name out there and will continue to grow.
Johnson & Johnson(JNJ-N) Rating
Ranking : 5 out of 5
Bullish - Buy Signals / Votes : 11
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 5
Total Signals / Votes : 16
Johnson & Johnson(JNJ-N) Frequently Asked Questions
What is Johnson & Johnson stock symbol?
Johnson & Johnson is a American stock, trading under the symbol JNJ-N on the New York Stock Exchange (JNJ). It is usually referred to as NYSE:JNJ or JNJ-N
Is Johnson & Johnson a buy or a sell?
In the last year, 16 stock analysts published opinions about JNJ-N. 11 analysts recommended to BUY the stock. 5 analysts recommended to SELL the stock. The latest stock analyst recommendation is TOP PICK. Read the latest stock experts' ratings for Johnson & Johnson.
Is Johnson & Johnson a good investment or a top pick?
Johnson & Johnson was recommended as a Top Pick by Brian Acker, CA on 2020-03-30. Read the latest stock experts ratings for Johnson & Johnson.
Why is Johnson & Johnson stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Johnson & Johnson worth watching?
16 stock analysts on Stockchase covered Johnson & Johnson In the last year. It is a trending stock that is worth watching.
What is Johnson & Johnson stock price?
On 2020-04-03, Johnson & Johnson (JNJ-N) stock closed at a price of $134.17.
